Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.


Use of erythropoiesis-stimulating agents (ESAs) presents a significant time and cost burden in the management of anemia of chronic kidney disease (CKD). We conducted a prospective, observational, activity-based costing study to estimate the health care personnel time and resulting direct medical costs associated with administering epoetin 3 times weekly to… (More)
DOI: 10.1111/j.1542-4758.2008.00308.x


  • Presentations referencing similar topics